Advertisement
Singapore markets close in 2 hours 19 minutes

  • Straits Times Index

    3,280.02
    -13.11 (-0.40%)
     

  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     

  • Hang Seng

    17,228.69
    +27.42 (+0.16%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,258.98
    -2,476.75 (-3.71%)
     

  • CMC Crypto 200

    1,390.87
    +8.30 (+0.60%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,330.80
    -7.60 (-0.33%)
     

  • Crude Oil

    82.93
    +0.12 (+0.14%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,570.29
    -1.19 (-0.08%)
     

  • Jakarta Composite Index

    7,152.44
    -22.10 (-0.31%)
     

  • PSE Index

    6,586.38
    +13.63 (+0.21%)
     

Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Prosper Junior Bakiny, The Motley Fool
·4-min read
Is Eli Lilly Stock a Buy Following This Competitor's Major Win?

Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%. The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.

Continue reading